carl_compliance said:MASHdoc_SA said: ...but the FDA says semaglutide...
Agreed, and ALT falling is not the same as fibrosis improving. Enzymes are a crude proxy; FIB-4 or elastography is what tells you about the thing that matters.
FDA_TrackerJim said:With resmetirom now available for MASH, combination approaches are being explored, so the standard of care in this area is moving faster than most…
This answered a question I did not know how to ask. Adding it to my notes with a link back to this thread.
Adding the clinical framing, because it changes how the question reads. Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third retelling.
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsDr.NephBHM_UK said:Most of what circulates confidently in this community traces back to one summary of one study, and the qualifier was dropped somewhere in the third…
Can confirm. Same sequence, different timescale.
Moderator note: two posts asking for a source have been merged into one. Please search the thread before asking again. Tagging this one for the weekly digest.